Eisai
4523.T
$34.28
Share price
0.76%
Change (1 day)
-35.73%
Change (1 year)
Categories
Eisai is a Japanese pharmaceutical company that is engaged in the R&D of drugs for the treatment of dementia and Alzheimer.
Revenue for Eisai (4523.T)
Revenue in 2024 (TTM): S$6.82 Billion
According to Eisai's latest financial reports the company's current revenue (TTM 
) is S$6.65 Billion. In 2023 the company made a revenue of S$6.98 Billion a decrease over the revenue in the year 2022 that were of S$7.44 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Eisai from 2009 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 (TTM) | S$6.82 B | -2.37% |
| 2023 | S$6.98 B | -6.17% |
| 2022 | S$7.44 B | -13.42% |
| 2021 | S$8.60 B | -2.53% |
| 2020 | S$8.82 B | 7.93% |
| 2019 | S$8.17 B | 5.12% |
| 2018 | S$7.77 B | 14.59% |
| 2017 | S$6.78 B | -4.69% |
| 2016 | S$7.12 B | 7.3% |
| 2015 | S$6.63 B | -3.46% |
| 2014 | S$6.87 B | -8.59% |
| 2013 | S$7.52 B | -12.75% |
| 2012 | S$8.61 B | -20.06% |
| 2011 | S$10.78 B | -10.87% |
| 2010 | S$12.09 B | 3.15% |
| 2009 | S$11.72 B |